scholarly journals MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis

Cells ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 2656
Author(s):  
Sandra Domingo ◽  
Cristina Solé ◽  
Teresa Moliné ◽  
Berta Ferrer ◽  
Josefina Cortés-Hernández
Keyword(s):  
Atopic Dermatitis ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Inflammatory Diseases ◽  
Biological Fluids ◽  
Cutaneous Lupus Erythematosus ◽  
Response To Treatment ◽  
Transcriptional Level ◽  
Detailed Knowledge ◽  
Cutaneous Lupus

MicroRNAs (miRNAs) are endogenous small non-coding RNA molecules that regulate the gene expression at a post-transcriptional level and participate in maintaining the correct cell homeostasis and functioning. Different specific profiles have been identified in lesional skin from autoimmune cutaneous diseases, and their deregulation cause aberrant control of biological pathways, contributing to pathogenic conditions. Detailed knowledge of microRNA-affected pathways is of crucial importance for understating their role in skin autoimmune diseases. They may be promising therapeutic targets with novel clinical implications. They are not only present in skin tissue, but they have also been found in other biological fluids, such as serum, plasma and urine from patients, and therefore, they are potential biomarkers for the diagnosis, prognosis and response to treatment. In this review, we discuss the current understanding of the role of described miRNAs in several cutaneous autoimmune diseases: psoriasis (Ps, 33 miRNAs), cutaneous lupus erythematosus (CLE, 2 miRNAs) and atopic dermatitis (AD, 8 miRNAs). We highlight their role as crucial elements implicated in disease pathogenesis and their applicability as biomarkers and as a novel therapeutic approach in the management of skin inflammatory diseases.

scholarly journals Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus

2018 ◽  
Vol 154 (6) ◽  
pp. 712 ◽  
Author(s):  
Elaine Kunzler ◽  
Linda S. Hynan ◽  
Benjamin F. Chong
Keyword(s):  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Cutaneous Lupus

Long-Term Risk of Autoimmune Diseases other than Systemic Lupus Erythematosus in Cutaneous Lupus Erythematosus-Alone Patients: A 10-Year Nationwide Cohort Study

Dermatology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Teng-Li Lin ◽  
Chun-Ying Wu ◽  
Chao-Kuei Juan ◽  
Yun-Ting Chang ◽  
Yi-Ju Chen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cohort Study ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Research Database ◽  
Systemic Lupus ◽  
Systemic Corticosteroids ◽  
Cutaneous Lupus

<b><i>Background:</i></b> Up to 25% of patients with cutaneous lupus erythematosus (CLE) can develop systemic lupus erythematosus (SLE). However, the risk of autoimmune diseases other than SLE in CLE patients who have only skin manifestations (CLE-alone) has rarely been explored. <b><i>Objective:</i></b> To investigate the long-term risk and independent factors of non-SLE autoimmune diseases among CLE-alone patients. <b><i>Method:</i></b> A nationwide cohort study using the Taiwanese National Health Insurance Research Database 1997–2013. CLE patients and matched subjects were included. Cumulative incidences of autoimmune diseases after 1 year of CLE-alone diagnosis were compared. Cox proportional hazard model was also performed. <b><i>Results:</i></b> A total of 971 CLE-alone patients and 5,175 reference subjects were identified. The 10-year cumulative incidence of autoimmune diseases other than SLE was significantly elevated in the CLE-alone cohort (9.00%, 95% confidence interval [CI] 6.72–11.29) than in the reference cohort (4.20%, 95% CI 3.53–4.87%) (<i>p</i> &#x3c; 0.001). CLE-alone was independently associated with non-SLE autoimmune diseases (adjusted hazard ratio 1.55, 95% CI 1.10–2.18). Among CLE-alone patients, females and those taking long-term systemic corticosteroids (a proxy for extensive disease) were associated with non-SLE autoimmune diseases after adjusting for the number of repeated autoimmune laboratory tests. <b><i>Conclusion:</i></b> CLE-alone is independently associated with future non-SLE autoimmune diseases.

PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus

2019 ◽  
Vol 11 (522) ◽  
pp. eaax1159 ◽  
Author(s):  
Xue Han ◽  
Matthew D. Vesely ◽  
Wendy Yang ◽  
Miguel F. Sanmamed ◽  
Ti Badri ◽  
...  
Keyword(s):  
T Cells ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Immune Cell ◽  
Cutaneous Lupus Erythematosus ◽  
Myeloid Cells ◽  
Discoid Lupus Erythematosus ◽  
Critical Element ◽  
Inhibitory Receptor ◽  
Cutaneous Lupus

Systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE) of the skin are autoimmune diseases characterized by inappropriate immune responses against self-proteins; the key elements that determine disease pathogenesis and progression are largely unknown. Here, we show that mice lacking immune inhibitory receptor VISTA or programmed death-1 homolog (PD-1H KO) on a BALB/c background spontaneously develop cutaneous and systemic autoimmune diseases resembling human lupus. Cutaneous lupus lesions of PD-1H KO mice have clustering of plasmacytoid dendritic cells (pDCs) similar to human DLE. Using mass cytometry, we identified proinflammatory neutrophils as critical early immune infiltrating cells within cutaneous lupus lesions of PD-1H KO mice. We also found that PD-1H is highly expressed on immune cells in human SLE, DLE lesions, and cutaneous lesions of MRL/lpr mice. A PD-1H agonistic monoclonal antibody in MRL/lpr mice reduces cutaneous disease, autoantibodies, inflammatory cytokines, chemokines, and immune cell expansion. Furthermore, PD-1H on both T cells and myeloid cells including neutrophils and pDCs could transmit inhibitory signals, resulting in reduced activation and function, establishing PD-1H as an inhibitory receptor on T cells and myeloid cells. On the basis of these findings, we propose that PD-1H is a critical element in the pathogenesis and progression of lupus, and PD-1H activation could be effective for treatment of systemic and cutaneous lupus.

scholarly journals AB007. Development and onset of autoimmune diseases in cutaneous lupus erythematosus patients

2019 ◽  
Vol 7 (S4) ◽  
pp. AB007-AB007
Author(s):  
Kevin Shi ◽  
Elaine Kunzler ◽  
Linda S. Hynan ◽  
Benjamin F. Chong
Keyword(s):  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Cutaneous Lupus
Sign in / Sign up

Export Citation Format

Share Document